Innocan Pharma Reports Q3 2023 Results Including US$3.334M Increase in Revenues Compared to Q3, 2022

Innocan Pharma Corporation Canada Israel Ontario

US$4.083M Revenues for Q3 2023 compared to US$749,000 for Q3 2022, representing an increase of 445%US$3.664M Gross Profit for Q3 2023 compared to USD 715,000 for Q3 2022, representing an increase of approximately 412%View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-reports-q3-2023-results-including-us3-334m-increase-in-revenues-compared-to-q3--2022--302001034.html